Literature DB >> 9432322

Decrease in gastric permeability to sucrose following cure of Helicobacter pylori infection.

R W Goodgame1, H M Malaty, H M el-Zimaity, D Y Graham.   

Abstract

BACKGROUND: Gastric sucrose permeability is a noninvasive marker that reliably increases in association with gastrointestinal injury due to use of nonsteroidal antiinflammatory drugs. Despite the effect of Helicobacter pylori infection on the gastric mucosa, in a previous study we were unable to demonstrate that H. pylori infection was associated with abnormal gastric sucrose permeability. Our goal in this study was to explore further whether H. pylori infection changed gastric permeability; therefore, we evaluated the effect of treatment of H. pylori infection on gastric permeability to sucrose and the relation of sucrose permeability to density of polymorphonuclear leukocytes.
MATERIALS AND METHODS: Five hundred milliliters of a solution containing 100 gm of sucrose was ingested by the subject at bedtime. Overnight urine was collected and assayed for sucrose by high-performance liquid chromatography. Sucrose permeability was assessed both before and approximately 4 weeks after anti-H. pylori therapy.
RESULTS: Seventeen asymptomatic H. pylori-infected volunteers participated; 8 were cured. Sucrose permeability was in the range commonly found in normal controls both before and after anti-H. pylori therapy (mean excretion, 76.3 mg; range, 13-171 mg). Gastric sucrose permeability correlated with the density of polymorphonulcear cell infiltration of the mucosa. Cure of the H. pylori infection was associated with a small but significant decrease in sucrose permeability (98.8 +/- 18 mg to 51.7 +/- 9.8 mg (p = .01). Sucrose permeability was greater in those with a high density of mucosal polymorphonuclear cells compared to those with lower scores (119.5 +/- 4 vs 71.4 +/- 13 for those with scores > or = 5 compared to scores < or = 4; p = .023). Failed therapy resulted in an increase in the mucosal density of polymorphonuclear infiltration and sucrose permeability (56.4 +/- 13 mg-99.7 +/- 19 mg pretreatment vs posttreatment, respectively; p = .031).
CONCLUSION: H. pylori gastritis causes a small but measurable increase in gastric permeability to sucrose that may reflect epithelial transmigration of neutrophils.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9432322     DOI: 10.1111/j.1523-5378.1997.tb00057.x

Source DB:  PubMed          Journal:  Helicobacter        ISSN: 1083-4389            Impact factor:   5.753


  12 in total

1.  Pathogenesis of increased sucrose permeability in H. pylori gastritis.

Authors:  D Y Graham
Journal:  Dig Dis Sci       Date:  2000-05       Impact factor: 3.199

2.  Significance of a novel sucrose permeability test using serum in the diagnosis of early gastric cancer.

Authors:  Tadayuki Shishido; Taketo Yamaguchi; Takeo Odaka; Masanori Seimiya; Hiromitsu Saisho; Fumio Nomura
Journal:  World J Gastroenterol       Date:  2005-11-28       Impact factor: 5.742

3.  Increased Gut Permeability in First-degree Relatives of Children with Irritable Bowel Syndrome or Functional Abdominal Pain.

Authors:  Mark McOmber; Danny Rafati; Kevin Cain; Sridevi Devaraj; Erica M Weidler; Margaret Heitkemper; Robert J Shulman
Journal:  Clin Gastroenterol Hepatol       Date:  2019-05-14       Impact factor: 11.382

4.  Helicobacter pylori activates myosin light-chain kinase to disrupt claudin-4 and claudin-5 and increase epithelial permeability.

Authors:  Jason P Fedwick; Tamia K Lapointe; Jonathan B Meddings; Philip M Sherman; Andre G Buret
Journal:  Infect Immun       Date:  2005-12       Impact factor: 3.441

5.  Effects of aspirin on gastroduodenal permeability in alcoholics and controls.

Authors:  Ashkan Farhadi; Ali Keshavarzian; Mary J Kwasny; Maliha Shaikh; Louis Fogg; Cynthia Lau; Jeremy Z Fields; Christopher B Forsyth
Journal:  Alcohol       Date:  2010-07-03       Impact factor: 2.405

Review 6.  Extraintestinal manifestations of Helicobacter pylori: a concise review.

Authors:  Frank Wong; Erin Rayner-Hartley; Michael F Byrne
Journal:  World J Gastroenterol       Date:  2014-09-14       Impact factor: 5.742

7.  Regulation of IL-18 in Helicobacter pylori infection.

Authors:  Kazuyoshi Yamauchi; Il-Ju Choi; Hong Lu; Hiroaki Ogiwara; David Y Graham; Yoshio Yamaoka
Journal:  J Immunol       Date:  2008-01-15       Impact factor: 5.422

Review 8.  Bacterial factors and immune pathogenesis in Helicobacter pylori infection.

Authors:  T Shimoyama; J E Crabtree
Journal:  Gut       Date:  1998-07       Impact factor: 23.059

Review 9.  Gastroretentive drug delivery systems for the treatment of Helicobacter pylori.

Authors:  Shan Zhao; Yan Lv; Jian-Bin Zhang; Bing Wang; Guo-Jun Lv; Xiao-Jun Ma
Journal:  World J Gastroenterol       Date:  2014-07-28       Impact factor: 5.742

10.  Helicobacter pylori PqqE is a new virulence factor that cleaves junctional adhesion molecule A and disrupts gastric epithelial integrity.

Authors:  Miguel S Marques; Ana C Costa; Hugo Osório; Marta L Pinto; Sandra Relvas; Mário Dinis-Ribeiro; Fátima Carneiro; Marina Leite; Ceu Figueiredo
Journal:  Gut Microbes       Date:  2021 Jan-Dec
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.